Alpha7beta1 Integrin Antibodies for Muscle Cell Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscular dystrophies, particularly those related to the laminin/dystroglycan/sarcoglycan/dystrophin complex, lack effective therapeutic options to address muscle malfunction and deterioration.
Innovation Solution
Development of a pharmaceutical agent that acts as an agonist for integrin heterodimers containing the beta-1 protein, specifically binding to the extracellular domain of α7, α6, or α3 proteins, to enhance muscle cell adhesion and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for muscular dystrophies are used, then muscle malfunction and deterioration are addressed, but there are no effective therapeutic options available
Solution Approach 1:
The patent uses integrin α7β1 as an intermediary receptor that mediates the interaction between laminin and muscle cells. By targeting this integrin with antibodies, the invention creates a therapeutic bridge that compensates for defective dystrophin or other laminin pathway proteins, enabling effective treatment without requiring correction of the underlying genetic defect.
Solution Approach 2:
The invention employs antibody molecules that copy or mimic the function of defective muscle proteins. The antibodies bind to integrin α7β1 and stabilize its interaction with laminin, effectively replicating the protective function that dystrophin or other laminin-associated proteins should provide, thereby offering a functional alternative to the defective native proteins.
2Strength
If integrin α7β1 is targeted with antibodies, then muscle cell adhesion to laminin is enhanced, but the complexity of the pharmaceutical agent increases
Solution Approach 1:
The patent modifies the pharmacological parameters by using monoclonal antibodies with specific binding affinities and efficacies. By optimizing antibody characteristics such as binding strength, half-life, and distribution, the invention achieves enhanced muscle cell adhesion while managing the complexity through standardized pharmaceutical development approaches.
3Reliability
If integrin α7β1 expression is upregulated, then compensation for dystrophin deficiency is achieved, but the expression level must be precisely controlled
Solution Approach 1:
The invention implements feedback control through antibody-mediated regulation of integrin α7β1 expression and activity. The monoclonal antibodies provide a controllable mechanism that can be adjusted to achieve optimal compensation levels, allowing precise control over the upregulation process and preventing excessive expression that could cause adverse effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pharmaceutical agent increases the adhesion of myoblasts and myotubes to laminin, potentially stabilizing muscle function and mitigating muscle injury in subjects with dystrophin deficiencies or mutations.
Implementation Method 1
an antibody that binds specifically to an epitope of integrin α7 protein
Implementation Method 2
integrin heterodimers that contain the β1 protein and that specifically bind laminin protein
Data Source
AI summary
Disclosed herein are pharmaceutical agents and compositions that activate integrin heterodimers that contain beta-1 integrin protein that specifically bind laminin protein. Such agents and compositions are useful for treating diseases related to muscle malfunction, including muscular dystrophies.